Please ensure Javascript is enabled for purposes of website accessibility

Merck Inks Multibillion-Dollar Deal With Seattle Genetics, Including Equity

By Todd Campbell – Sep 14, 2020 at 5:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Merck is acquiring $1 billion in Seattle Genetics shares as part of a wide-ranging collaboration agreement.

Merck & Co (MRK 1.66%) and Seattle Genetics (SGEN 0.64%) have agreed to terms in a licensing and equity-investment deal that could be worth $4.2 billion to Seattle Genetics.

Specifically, Merck's paying $600 million upfront and up to $2.6 billion in progress-determined milestone payments for global co-development and co-commercial rights to Seattle Genetics ladiratuzumab vedotin, an antibody-drug conjugate targeting various cancer indications. Merck's also acquiring $1 billion in shares in Seattle Genetics at $200 per share, which is a significant premium to Seattle Genetics' $150 closing price on Friday.

Two business people shaking hands.

IMAGE SOURCE: GETTY IMAGES.

The healthcare companies plan to evaluate ladiratuzumab vedotin as monotherapy and in combination with Merck's mega-blockbuster anti-PD-1 therapy, Keytruda, in triple-negative breast cancer, hormone receptor-positive breast cancer, and other solid tumor cancers.

Separately, Merck also obtained certain ex-U.S. rights to Tukysa, a HER2-positive breast cancer drug, from Seattle Genetics for $125 million upfront and $65 million in potential milestone payments. Merck will pay $85 million in prepaid research and development costs and tiered royalties on sales within its licensed territories outside the U.S., Canada, and Europe.

In April, Tukysa won FDA approval for use alongside Herceptin and Xeloda in previously treated metastatic HER2-positive breast cancer. In clinical trials, adding Tukysa to Herceptin and Xeloda improved progression-free survival and overall survival in previously treated metastatic HER2-positive breast cancer patients. Seattle Genetics reported Tukysa sales of $16 million in the second quarter.

Overall, the deal provides Seattle Genetics with significant financial flexibility and marketing might. For perspective, its three commercial-stage drugs -- Adcetris, Padcev, and Tukysa -- contributed $240.5 million in revenue in the second quarter, up 51% from last year.

 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$87.55 (1.66%) $1.43
Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$137.70 (0.64%) $0.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.